English | Español

Pharmaceuticals

+ Pharmaceuticals
Patient Daily | Jul 31, 2026

Capricor CEO considers legal action after FDA panel votes against DMD therapy
+ Pharmaceuticals
Patient Daily | Jul 31, 2026

Alnylam cuts full-year guidance for TTR franchise, loses $10.8 billion in market value
+ Regulatory
L. R. Alvarez | Jul 30, 2026

TPA's Ross Marchand on 340B: 'Taxpayers are picking up the tab for the program's many failures and mission creep'
+ Pharmaceuticals
Patient Daily | Jul 30, 2026

Microbial metabolites may improve functional cure rates for hepatitis B
+ Pharmaceuticals
Patient Daily | Jul 30, 2026

NYU Langone and Dana-Farber launch new oncology platform to support cancer care
+ Pharmaceuticals
Patient Daily | Jul 30, 2026

Dual immunotherapy with chemotherapy shows activity in HER2-negative breast cancer trial
+ Pharmaceuticals
Patient Daily | Jul 30, 2026

Texas A&M researchers develop AI tools to streamline tuberculosis drug discovery process
+ Pharmaceuticals
Patient Daily | Jul 30, 2026

FDA advisory committee votes in favor of Replimune’s melanoma therapy despite data concerns

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation